human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed)

This medicine is now withdrawn from use in the European Union.


The marketing authorisation for Silgard has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 02/04/2019

Authorisation details

Product details
Agency product number
Active substance
  • human papillomavirus type 6 L1 protein
  • human papillomavirus type 11 L1 protein
  • human papillomavirus type 16 L1 protein
  • human papillomavirus type 18 L1 protein
International non-proprietary name (INN) or common name
human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed)
Therapeutic area (MeSH)
  • Papillomavirus Infections
  • Uterine Cervical Dysplasia
  • Condylomata Acuminata
  • Immunization
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Merck Sharp Dohme Ltd
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Hertford Road
EN11 9BU
United Kingdom

Product information

18/02/2019 Silgard - EMEA/H/C/000732 - WS/1349/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

Silgard is a vaccine for use from the age of 9 years for the prevention of:

  • premalignant genital lesions (cervical, vulvar and vaginal), premalignant anal lesions, cervical cancers and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types;
  • genital warts (condyloma acuminata) causally related to specific HPV types.

See sections 4.4 and 5.1 for important information on the data that support this indication.

The use of Silgard should be in accordance with official recommendations.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
1 rating
1 rating
1 rating